For the second time this summer, a candidate drug has failed to slow the rate of mental decline in large trials of patients with Alzheimer's disease. But some hope remains that the compound could help patients with milder forms of the disease.
On Friday, Eli Lilly announced that two late-stage trials of its amyloid-grabbing antibody solanezumab
did not protect patients' cognitive abilities. The results come just
weeks after Pfizer and Johnson & Johnson announced their
anti-amyloid antibody bapineuzumab failed in clinical trials (see "A New Setback for Alzheimer's Drugs").